The global pregabalin market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Pregabalin is a medication that is used to treat epilepsy and anxiety. It is also used to treat nerve pain that can be caused by different conditions including diabetes and shingles, or an injury. The major factor driving the demand for the global pregabalin market during the forecast period is the increasing prevalence of epilepsy across the globe. Moreover, the market is also growing due to the growing geriatric population coupled with the increasing prevalence of diabetes as well as neuropathic pain among people globally.

According to the World Health Organization (WHO), in 2019, epilepsy is one of the most common neurological diseases globally with around 50 million people diagnosed with it. Additionally, almost 80% of people with epilepsy live in low and middle-income countries and up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated. However, the risk of mortality is three times higher in people with epilepsy than in the general population. Hence the rising prevalence of epilepsy is driving the demand for pregabalin for treatment which in turn is boosting its market growth.

Some major players in the market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Cipla Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2020, Sawai announced the launch of the first generic version of the Lyrica pregabalin brand in Japan.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By Application

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Cipla Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Pregabalin Market Report by Segment

By Type

• Capsules
• Oral Solutions
• Others

By Application

• Epilepsy
• Neuropathic Pain
• Anxiety Disorder
• Others

Global Pregabalin Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa